F-star Therapeutics, Inc. (NASDAQ:FSTX) Given Average Rating of “Hold” by Analysts

F-star Therapeutics, Inc. (NASDAQ:FSTXGet Rating) has been given an average rating of “Hold” by the six brokerages that are currently covering the firm, MarketBeat Ratings reports. Five analysts have rated the stock with a hold recommendation and one has given a buy recommendation to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $33.00.

Several equities analysts have weighed in on FSTX shares. Laidlaw cut F-star Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, June 23rd. William Blair cut F-star Therapeutics from an “outperform” rating to a “market perform” rating in a report on Thursday, June 23rd. LADENBURG THALM/SH SH cut F-star Therapeutics from a “buy” rating to a “neutral” rating in a report on Thursday, June 23rd. SVB Leerink cut F-star Therapeutics from an “outperform” rating to a “market perform” rating in a report on Thursday, June 23rd. Finally, HC Wainwright cut F-star Therapeutics from a “buy” rating to a “neutral” rating in a report on Friday, July 15th.

Hedge Funds Weigh In On F-star Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Prelude Capital Management LLC acquired a new position in F-star Therapeutics in the 2nd quarter worth about $227,000. Formidable Asset Management LLC bought a new stake in shares of F-star Therapeutics in the 2nd quarter valued at about $382,000. PenderFund Capital Management Ltd. bought a new stake in shares of F-star Therapeutics in the 2nd quarter valued at about $185,000. Knott David M Jr bought a new stake in shares of F-star Therapeutics in the 2nd quarter valued at about $472,000. Finally, BCK Capital Management LP bought a new stake in shares of F-star Therapeutics in the 2nd quarter valued at about $326,000. Institutional investors and hedge funds own 33.33% of the company’s stock.

F-star Therapeutics Price Performance

Shares of NASDAQ FSTX opened at $6.49 on Tuesday. The stock has a market capitalization of $140.05 million, a PE ratio of -4.33 and a beta of 0.97. The company has a debt-to-equity ratio of 0.16, a current ratio of 4.23 and a quick ratio of 4.23. The business has a fifty day moving average price of $6.44 and a two-hundred day moving average price of $4.44. F-star Therapeutics has a fifty-two week low of $2.07 and a fifty-two week high of $8.36.

About F-star Therapeutics

(Get Rating)

F-star Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118 and is being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck cancer patients.

Featured Stories

Analyst Recommendations for F-star Therapeutics (NASDAQ:FSTX)

Receive News & Ratings for F-star Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for F-star Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.